Concord Drugs Past Earnings Performance
Past criteria checks 2/6
Concord Drugs has been growing earnings at an average annual rate of 7.1%, while the Pharmaceuticals industry saw earnings growing at 17.2% annually. Revenues have been declining at an average rate of 2.1% per year. Concord Drugs's return on equity is 1.4%, and it has net margins of 1.1%.
Key information
7.1%
Earnings growth rate
5.2%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | -2.1% |
Return on equity | 1.4% |
Net Margin | 1.1% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Concord Drugs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 449 | 5 | 61 | 0 |
31 Dec 23 | 416 | 10 | 57 | 0 |
30 Sep 23 | 423 | 17 | 55 | 0 |
30 Jun 23 | 485 | 13 | 51 | 0 |
31 Mar 23 | 521 | 10 | 49 | 0 |
31 Dec 22 | 553 | 9 | 104 | 0 |
30 Sep 22 | 552 | 8 | 103 | 0 |
30 Jun 22 | 513 | 11 | 102 | 0 |
31 Mar 22 | 590 | 16 | 100 | 0 |
31 Dec 21 | 519 | 19 | 45 | 0 |
30 Sep 21 | 467 | 42 | 42 | 0 |
30 Jun 21 | 535 | 38 | 39 | 0 |
31 Mar 21 | 514 | 33 | 38 | 0 |
31 Dec 20 | 561 | 30 | 38 | 0 |
30 Sep 20 | 588 | 4 | 36 | 0 |
30 Jun 20 | 563 | 4 | 36 | 0 |
31 Mar 20 | 514 | 3 | 36 | 0 |
31 Dec 19 | 527 | 4 | 31 | 0 |
30 Sep 19 | 510 | 4 | 30 | 0 |
30 Jun 19 | 484 | 4 | 33 | 0 |
31 Mar 19 | 482 | 4 | 26 | 0 |
31 Dec 18 | 550 | 1 | 21 | 0 |
30 Sep 18 | 517 | 4 | 21 | 0 |
30 Jun 18 | 440 | 5 | 19 | 0 |
31 Mar 18 | 519 | 3 | 21 | 0 |
31 Dec 17 | 522 | -13 | 32 | 0 |
30 Sep 17 | 554 | -4 | 31 | 0 |
30 Jun 17 | 656 | 1 | 28 | 0 |
31 Mar 17 | 576 | 2 | 28 | 0 |
31 Dec 16 | 493 | 13 | 26 | 0 |
30 Sep 16 | 535 | 19 | 22 | 0 |
30 Jun 16 | 515 | 21 | 19 | 0 |
31 Mar 16 | 509 | 17 | 16 | 0 |
31 Dec 15 | 474 | 27 | 8 | 0 |
30 Sep 15 | 443 | 9 | 7 | 0 |
30 Jun 15 | 421 | 8 | 6 | 0 |
31 Mar 15 | 404 | 7 | 6 | 0 |
31 Dec 14 | 388 | 4 | 13 | 0 |
30 Sep 14 | 375 | 4 | 13 | 0 |
30 Jun 14 | 359 | 4 | 7 | 0 |
31 Mar 14 | 341 | 3 | 12 | 0 |
31 Dec 13 | 317 | 6 | 11 | 0 |
30 Sep 13 | 299 | 8 | 11 | 0 |
Quality Earnings: 538965 has high quality earnings.
Growing Profit Margin: 538965's current net profit margins (1.1%) are lower than last year (1.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 538965's earnings have grown by 7.1% per year over the past 5 years.
Accelerating Growth: 538965's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 538965 had negative earnings growth (-52.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (18.2%).
Return on Equity
High ROE: 538965's Return on Equity (1.4%) is considered low.